Kornam, pills 2mg, 20pcs

Composition

1 tablet contains terazosin (in the form of hydrochloride dihydrate) 2 or 5 mg;

20 pcs. in the package.

Pharmacological action

Kornam is a blocker of peripheral postsynaptic_a1-adrenergic receptors.

Causes dilation of arterioles and venules, reduces OPSS and venous return to the heart, resulting in a decrease in blood pressure.

After taking a single dose of the drug, the hypotensive effect persists for 24 hours.

_{By blocking a1}-adrenergic receptors of the smooth muscles of the prostate and bladder neck, the drug contributes to the normalization of urination in patients with benign prostatic hyperplasia.

The drug contributes to the normalization of lipid metabolism: it reduces the content of cholesterol, triglycerides and low-and very low-density lipoproteins in the blood, while increasing the amount of high-density lipoproteins.

With the systematic use of Cornam, regression of left ventricular hypertrophy is noted.

Indications

• Benign prostatic hyperplasia.
• Arterial hypertension.

Contraindications

• Children’s age.
• Hypersensitivity to the drug.

With caution, the drug should be prescribed for angina, CHD, hepatic or renal failure, impaired cerebral circulation, type 1 diabetes mellitus.

Side effects

• In the treatment of benign prostatic hyperplasia

From the cardiovascular system: rarely-orthostatic hypotension. From the central nervous system: drowsiness, dizziness, asthenia. Other: nasal congestion.

• In the treatment of arterial hypertension

From the cardiovascular system: orthostatic hypotension – ” first dose effect “(observed in 1% of patients, mainly receiving diuretics or beta-blockers at the same time), manifested by dizziness, tachycardia, possible fainting states; rarely – palpitation, peripheral edema, nasal congestion. From the central nervous system: rarely-dizziness, asthenia, drowsiness, impaired clarity of visual perception. From the hematopoietic system: decreased (due to hemodilution) hematocrit, hemoglobin, leukopenia, hypoproteinemia, hypoalbuminemia. Other: rarely-decreased potency, nausea.

Interaction

With simultaneous use of Kornam and beta-blockers, diuretics, calcium channel blockers, ACE inhibitors, the antihypertensive effect may increase. Special care should be taken when prescribing terazosin and central-acting antihypertensive drugs at the same time.

Terazosin absorption decreases with simultaneous use of adsorbents and antacids.

Adrenomimetics weaken the effect of terazosin.

Concomitant use of terazosin and NSAIDs may reduce the antihypertensive effect due to suppression of prostaglandin synthesis and fluid retention and sodium ions.

How to take, course of use and dosage

In benign prostatic hyperplasia, the initial dose is 1 mg once a day before bedtime.

Gradually, the dose is increased to 2-10 mg / day until the optimal effect is achieved.

The therapeutic effect is usually noted 2 weeks after the start of treatment.

To achieve a lasting effect, the course of treatment should be 4-6 weeks.

With arterial hypertension, the drug is prescribed at an initial dose of 1 mg / day. before bedtime.

Gradually, the dose is increased until a clinical effect is achieved.

The maintenance dose is 1-10 mg 1 time/day.

The maximum daily dose is 20 mg.

In case of temporary discontinuation of the drug, treatment is resumed according to the same scheme.

Overdose

Symptoms:  marked decrease in blood pressure, impaired coordination of movements, fainting.

Treatment:  it is necessary to lay the patient down by lowering the head end of the bed.

If necessary, appoint hypertensive drugs, intravenous fluid use.

Hemodialysis is not effective.

Special instructions

To prevent orthostatic hypotension, treatment should be started with the appointment of Korama at a dose of 1 mg/day. before bed, after which the patient must remain in bed for 6-8 h.

the Risk of orthostatic hypotension (“effect of the first dose”) is highest within 30-90 minutes after intake of the drug and increased in patients receiving both beta-blockers and diuretics, with a decrease in BCC, hyposalemia diet, as well as the resumption of treatment after a break (a few days).

In case of temporary discontinuation of treatment, therapy is resumed with the same dose. During treatment, the level of specific prostate antigen does not change. Before starting therapy for benign prostatic hyperplasia, it is necessary to exclude prostate cancer.

The patient should be informed about the increased risk of developing orthostatic hypotension when drinking alcohol, standing for a long time or performing physical exercises, as well as when the weather is hot.

Within 12 hours after taking the first dose, after increasing the dose or interrupting therapy, it is not recommended to engage in potentially dangerous activities that require increased attention and speed of psychomotor reactions.

Composition

Tablet Form of production

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years

Active ingredient

Terazosin

Conditions of release from pharmacies

By prescription

Dosage form

Tablets